SAB BIOTHERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences
SAB BIOTHERAPEUTICS, INC. (SABS) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences of $99.30 thousand as of 2021-12-31, per its 10-K/A filed 2023-04-28.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences · last filed 2023-04-28
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $99.30K.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $84.55K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences |
|---|---|
| 2021-12-31 | $99.30K 10-K/A · filed 2023-04-28 |
| 2020-12-31 | $84.55K 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |